Pediatrix Medical Group (NYSE:MD) Price Target Raised to $16.50 at UBS Group

Pediatrix Medical Group (NYSE:MD) had its price objective increased by UBS Group from $10.50 to $16.50 in a research report sent to investors on Tuesday,Benzinga reports. UBS Group currently has a neutral rating on the stock.

A number of other research firms have also recently commented on MD. Truist Financial raised their price target on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Jefferies Financial Group raised their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft raised their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. StockNews.com upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Finally, Mizuho lifted their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $16.10.

Pediatrix Medical Group Price Performance

Shares of NYSE MD opened at $15.76 on Tuesday. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $16.41. The firm has a fifty day simple moving average of $12.08 and a 200 day simple moving average of $9.64. The company has a market capitalization of $1.35 billion, a PE ratio of -5.15, a P/E/G ratio of 2.38 and a beta of 1.55. The company has a quick ratio of 1.38, a current ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same period last year, the company posted $0.29 earnings per share. On average, sell-side analysts forecast that Pediatrix Medical Group will post 1.21 EPS for the current year.

Insider Activity

In related news, CEO James D. Swift sold 11,100 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares in the company, valued at approximately $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO James D. Swift sold 11,100 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares in the company, valued at approximately $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the transaction, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 35,538 shares of company stock worth $373,664 over the last three months. 2.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP raised its position in Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after acquiring an additional 7,241,400 shares during the period. Dana Investment Advisors Inc. raised its position in Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after acquiring an additional 455,785 shares during the period. Boston Partners raised its position in Pediatrix Medical Group by 34.0% in the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after acquiring an additional 453,254 shares during the period. Cubist Systematic Strategies LLC raised its position in Pediatrix Medical Group by 639.4% in the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock worth $2,192,000 after acquiring an additional 251,072 shares during the period. Finally, ClariVest Asset Management LLC bought a new stake in Pediatrix Medical Group in the second quarter worth about $1,721,000. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.